WO2024069592 - N-(5-SUBSTITUTED-[(1,3,4-THIADIAZOLYL) OR (1,3-THIAZOLYL)](SUBSTITUTED)CARBOXAMIDE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING THE AMIDE COMPOUNDS AND OF THEIR USE
National phase entry:
Publication Number
WO/2024/069592
Publication Date
04.04.2024
International Application No.
PCT/IB2023/059814
International Filing Date
29.09.2023
Title **
[English]
N-(5-SUBSTITUTED-[(1,3,4-THIADIAZOLYL) OR (1,3-THIAZOLYL)](SUBSTITUTED)CARBOXAMIDE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING THE AMIDE COMPOUNDS AND OF THEIR USE
[French]
COMPOSÉS DE N-([(1, 3,4-THIADIAZOLYLE) SUBSTITUÉ EN POSITION 5 OU (1,3-THIAZOLYL)](SUBSTITUÉ)CARBOXAMIDE, COMPOSITIONS PHARMACEUTIQUES ET PROCÉDÉS DE PRÉPARATION DE COMPOSÉS AMIDES ET LEUR UTILISATION
Applicants **
REPARE THERAPEUTICS INC.
Inventors
LIU, Bingcan
PERRYMAN, Alexander
MOCHIRIAN, Philippe
GALLANT, Michel
BENDAHAN, David
SURPRENANT, Simon
SZYCHOWSKI, Janek
DIETRICH, Evelyne
SOW, Boubacar
BUBENIK, Monica
MORRIS, Stephen
Priority Data
PCT/CA2022/051446
29.09.2022
CA
63/455,612
30.03.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CIPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3583 | |
| EPO | Filing, Examination, Granting | 20096 | |
| Japan | Filing, Examination, Granting | 2371 | |
| South Korea | Filing, Examination, Granting | 2635 | |
| USA | Filing, Examination, Granting | 7240 |
Total:
35,925
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present application discloses specific compounds of Formula (I) and their use in therapy, in particular, their use as Polymerase Theta (Polθ) inhibitors for the treatment of cancer. The application further discloses the use of a combination comprising a compound of Formula (I) and a radiotherapy or a radioligand in therapy, in particular, the use of specific compounds of Formula (I) as a Polymerase Theta (Polθ) inhibitor in combination with a radiotherapy or a radioligand for the treatment of cancer.[French]
La présente demande concerne des composés spécifiques de formule (I) et leur utilisation en thérapie, en particulier, leur utilisation en tant qu'inhibiteurs de polymérase thêta (Polθ) pour le traitement du cancer. La demande concerne en outre l'utilisation d'une combinaison comprenant un composé de formule (I) et une radiothérapie ou un radioligand en thérapie, en particulier l'utilisation de composés spécifiques de formule (I) en tant qu'inhibiteur de polymérase thêta (Polθ) en combinaison avec une radiothérapie ou un radioligand pour le traitement du cancer.